Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q1
Sell
-19,700
Closed -$5.67M 769
2023
Q4
$5.67M Buy
+19,700
New +$5.37M 0.21% 100
2023
Q3
Sell
-32,800
Closed -$7.28M 717
2023
Q2
$7.28M Buy
+32,800
New +$7.61M 0.26% 60
2023
Q1
Sell
-42,300
Closed -$11.1M 752
2022
Q4
$11.1M Buy
+42,300
New +$11.3M 0.51% 26
2020
Q1
Sell
-31,200
Closed -$7.52M 1213
2019
Q4
$7.52M Buy
31,200
+21,100
+209% +$4.65M 0.11% 140
2019
Q3
$1.95M Buy
+10,100
New +$1.94M 0.04% 439
2018
Q2
Sell
-21,600
Closed -$3.68M 1593
2018
Q1
$3.68M Sell
21,600
-28,500
-57% -$5.23M 0.06% 294
2017
Q4
$8.71M Buy
50,100
+400
+0.8% +$70.8K 0.12% 141
2017
Q3
$9.27M Buy
49,700
+28,400
+133% +$5.03M 0.13% 127
2017
Q2
$3.67M Sell
21,300
-17,200
-45% -$2.8M 0.04% 433
2017
Q1
$6.32M Sell
38,500
-70,700
-65% -$11.7M 0.08% 237
2016
Q4
$16M Sell
109,200
-146,900
-57% -$22.1M 0.16% 72
2016
Q3
$42.7M Buy
256,100
+96,600
+61% +$16.3M 0.53% 32
2016
Q2
$24.3M Buy
159,500
+22,500
+16% +$3.5M 0.27% 36
2016
Q1
$20.5M Buy
+137,000
New +$20.4M 0.34% 35

Other funds holding AMGN

Paloma Partners's AMGN Position: Q4 2024 in Review

Paloma Partners sold out of Amgen (AMGN) in Q4 2024, closing a stake of 1,997 shares — an estimated $643K sold.

Paloma Partners first reported a position in AMGN in Q2 2013 and held it in 36 quarters. The position peaked at $36.2M in Q3 2018. 2,855 funds tracked by Wall St. Rank hold AMGN as of Q4 2024.

  • Paloma Partners reported no remaining Amgen position as of Q4 2024 after selling out during the quarter.
  • Paloma Partners sold 1,997 Amgen shares in Q4 2024, an estimated $643K.
  • Paloma Partners first reported a position in Amgen in Q2 2013 and held it in 36 quarters.
  • Paloma Partners's Amgen position peaked at $36.2M in Q3 2018.
  • 2,855 funds tracked by Wall St. Rank held Amgen as of Q4 2024.

Based on Paloma Partners's 13F filing for Q4 2024, filed 14 Feb 2025.